Their Justice-Driven Road to Prosecution: Errant Gene Therapeutics vs. Third Rock Ventures

Boston, the world’s biotech capital, became the location for one of biotech’s most important but not well-known legal battles. On September 25th, 2019 in Massachusetts Superior Court, Errant Grant Therapeutics (EGT) filed their long-awaited legal complaint against Third Rock Ventures, LLC (TRV) and Nick Leschly, its CEO. 

The accusations? As stated in Civil Action No. 19-1832, plaintiff EGT’s complaint against TRV and Leschy addresses an alleged “tortious interference, misappropriation of trade secrets civil conspiracy, [and] unjust enrichment.” This little-known case is important, as it seeks to ensure that the often winner-take-all world of drug development is governed by the rule of law. 

As previously reported by TrialSite News, EGT and TRV have been at it for quite some time. It is a riveting tale that has been unfolding since 1992 when Patrick Girondi’s eldest son was diagnosed with Thalassemia, a fatal blood disease. This spurred his interest in learning about the disease and his dedication to finding a cure for his son (and for other children afflicted with deadly rare diseases). Girondi later founded EGT in the year of 2003.

For additional background coverage ...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

Personal
$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
Professional
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee